Anti-VEGF therapy may aid visual acuity in some nAMD patients
(HealthDay)—For about 20 percent of patients with neovascular age-related macular degeneration (nAMD), useful visual acuity (VA) is preserved with anti-vascular endothelial growth factor (VEGF) treatment, according to a study published online Oct. 15 in JAMA Ophthalmology. Robert P. Finger, M.D., Ph.D., from the University of Bonn in Germany, and colleagues conducted multistate modeling using real-world cohort data of 3,192 patients […]
Continue reading »